Institutional members access full text with Ovid®

Share this article on:


Giannakaki-Zimmermann, Helena, MD; Munk, Marion R., MD, PhD; Dysli, Chantal, MD; Ebneter, Andreas, MD, PhD; Wolf, Sebastian, MD, PhD; Zinkernagel, Martin S., MD, PhD

doi: 10.1097/ICB.0000000000000589
Case Report: PDF Only

Background/Purpose: To investigate the retinal and choroidal vasculature in patients with torpedo maculopathy with optical coherence tomography-angiography (OCT-A).

Methods: Retrospective case series of four patients who were examined at the department of Ophthalmology at the University Hospital Bern. Main Outcome was the lesion size over time in OCT-A and fundus autofluorescence.

Results: Three patients had Type I and 1 patient had Type II torpedo maculopathy. Torpedo maculopathy lesion size remained stable in all patients over a mean period of observation of three years in OCT-A and fundus autofluorescence. The choriocapillaris network was attenuated focally within the lesion in OCT-A in all four cases. The lesion size in fundus autofluorescence was 2.77 mm2 and therefore comparable with the lesion size in OCT-A of 2.75 mm2.

Conclusion: OCT-A signal of the choriocapillaris was reduced within the cleft in both types of torpedo maculopathy. Whether the changes represent the primary site of malformation or whether these findings are the consequence of a defect in the retinal pigment epithelium remains speculative.

Investigating the retinal and choroidal vasculature in patients with torpedo maculopathy with optical coherence tomography angiography we found an attenuated choriocapillaris within the lesion in all our four cases. Lesion size remained stable during approximately 3 years. The pathophysiology though remains speculative.

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Reprint requests: Helena Giannakaki-Zimmermann, MD, Department Ophthalmology, Inselspital, University Hospital, Universität Bern, CH-3010 Bern, Switzerland; e-mail:

The authors received nonfinancial support from Carl Zeiss Meditec AG.

© 2018 by Ophthalmic Communications Society, Inc.